Latest news
SKYSCRAPER-03 Trial: Critical Setback for TIGIT Consolidation in Stage III NSCLC - OncodailyOncodaily · Sat, 08 Aug 2026 11:36:12 GMTProton Pump Inhibitor, Antibiotic Exposure Linked to Worse Durvalumab Outcomes in Unresectable Stage III NSCLC - The ASCO PostThe ASCO Post · Mon, 27 Jul 2026 14:59:46 GMT